Bio-Gate

The management board of Bio-Gate, with the supervisory board’s approval, has resolved a capital increase from authorized capital and plans to issue up to 407,747 new shares. The shares will be offered at €2.80 each in a private placement; the measure is expected to generate gross proceeds of up to approximately €1,141,691.60. At the same time, management set the conditions for the rights issue approved by the annual general meeting on 30 June 2026 (subscription price €2.80, subscription period 30 July to 13 August 2026, expected trading date around 26 August 2026). The proceeds are intended to strengthen short-term liquidity, creditworthiness and equity and to support the growth strategy. » Más en de.investing.com

At the annual general meeting on 30 June 2026, Bio-Gate will propose a simplified capital reduction of EUR 8,154,952.00 by consolidating shares at a ratio of 5:1, followed by a cash capital increase with subscription rights for existing shareholders of up to EUR 650,000.00 through the issuance of up to 650,000 new shares. Shares not subscribed to will be offered to selected institutional investors; anchor shareholders have signaled their willingness to exercise their subscription rights and to oversubscribe. The measures aim to cover losses and impairments and to strengthen financial stability and the company’s operational projects in the wound care and coatings area. » Más en finanzen.net

Bio-Gate recorded revenue of €3.44 million in the first half of 2025, slightly below the prior year, but improved EBITDA to -€0.72 million (H1 2024: -€0.96 million). Analysts attribute the improvement to lower material expenses, greater in-house production depth and optimized cost control, and they confirm the price target and a positive rating. The development is intended to show that the measures taken are working. » Más en finanzen.net